Poltreg S.A. (PTG.WA)
PLN 35.3
(-1.94%)
PLN 35.3
(-1.94%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.39 Million PLN | 40.04% |
| 2022 | 999 Thousand PLN | -9.1% |
| 2021 | 1.09 Million PLN | 57.0% |
| 2020 | 700 Thousand PLN | 40.0% |
| 2019 | 500 Thousand PLN | 0.0% |
| 2018 | - PLN | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 100 Thousand PLN | -50.0% |
| 2024 Q2 | - PLN | -100.0% |
| 2023 Q2 | 300 Thousand PLN | -49.92% |
| 2023 Q4 | 200 Thousand PLN | -33.33% |
| 2023 FY | 1.39 Million PLN | 40.04% |
| 2023 Q1 | 599 Thousand PLN | 99.67% |
| 2023 Q3 | 300 Thousand PLN | 0.0% |
| 2022 FY | 999 Thousand PLN | -9.1% |
| 2022 Q4 | 300 Thousand PLN | 200.0% |
| 2022 Q3 | 100 Thousand PLN | -74.94% |
| 2022 Q2 | 399 Thousand PLN | 99.5% |
| 2022 Q1 | 200 Thousand PLN | -60.0% |
| 2021 Q1 | 100 Thousand PLN | -50.0% |
| 2021 FY | 1.09 Million PLN | 57.0% |
| 2021 Q4 | 500 Thousand PLN | 151.26% |
| 2021 Q3 | 199 Thousand PLN | -33.67% |
| 2021 Q2 | 300 Thousand PLN | 200.0% |
| 2020 Q2 | 100 Thousand PLN | 0.0% |
| 2020 Q3 | 300 Thousand PLN | 200.0% |
| 2020 Q4 | 200 Thousand PLN | -33.33% |
| 2020 FY | 700 Thousand PLN | 40.0% |
| 2020 Q1 | 100 Thousand PLN | 0.0% |
| 2019 FY | 500 Thousand PLN | 0.0% |
| 2018 FY | - PLN | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Bioceltix S.A. | - PLN | -Infinity% |
| BIOTON S.A. | 181.63 Million PLN | 99.23% |
| Captor Therapeutics Spolka Akcyjna | 13.2 Million PLN | 89.402% |
| Mabion S.A. | 151.67 Million PLN | 99.078% |
| Molecure S.A. | 100.00 PLN | -1398900.0% |
| NanoGroup S.A. | 2019.00 PLN | -69191.729% |
| Pharmena S.A. | 9.83 Million PLN | 85.778% |
| Pure Biologics Spólka Akcyjna | 95 Thousand PLN | -1372.632% |
| Ryvu Therapeutics S.A. | 46.86 Million PLN | 97.015% |
| Synthaverse S.A. | 58.6 Million PLN | 97.613% |
| Urteste S.A. | - PLN | -Infinity% |